Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL ER versus METRONIDAZOLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL ER versus METRONIDAZOLE HYDROCHLORIDE.
FLAGYL ER vs METRONIDAZOLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.
750 mg orally once daily for 10 days for bacterial vaginosis.
Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
7-8 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Renal 60-80% as unchanged drug and metabolites; fecal 6-15%; biliary minor.
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic